Stephen William Bunting
Directeur/Membre du Conseil chez Abingworth Bioventures IV GP Ltd.
Profil
Stephen William Bunting is the founder of Hexagen Plc, Astex Therapeutics Ltd., deVGen NV.
He currently holds director positions at Abingworth Bioventures V GP Ltd., Abingworth Bioventures IV GP Ltd., Abingworth Ventures (GP) Ltd., Abingworth Trustee Ltd., Elkinbrook Ltd., and Abingworth Management Holdings Ltd.
He formerly held various director positions at Aurora Biosciences Corp., Cantab Pharmaceuticals Plc, Akubio Ltd., Galapagos NV, Genetic Therapy, Inc., Galapagos Biotech Ltd., Ablynx NV, Abingworth Bioventures IIA GP Ltd., and Prosensa Holding NV.
He was also the Chairman of Abingworth LLP from 2011 to 2019 and the Managing Partner of Abingworth Management Ltd.
He holds a doctorate degree from The University of Reading.
Postes actifs de Stephen William Bunting
| Sociétés | Poste | Début |
|---|---|---|
| Abingworth Bioventures IV GP Ltd. | Directeur/Membre du Conseil | - |
| Abingworth Bioventures V GP Ltd. | Directeur/Membre du Conseil | - |
| Abingworth Trustee Ltd. | Directeur/Membre du Conseil | - |
| Abingworth Ventures (GP) Ltd. | Directeur/Membre du Conseil | - |
| Elkinbrook Ltd. | Directeur/Membre du Conseil | - |
Abingworth Management Holdings Ltd.
 Abingworth Management Holdings Ltd. Investment ManagersFinance Part of Abingworth LLP, Abingworth Management Holdings Ltd. is a British company that engages in the management of investment funds. The company is based in London, UK. Founded in 1989. | Directeur/Membre du Conseil | - |
Anciens postes connus de Stephen William Bunting
| Sociétés | Poste | Fin |
|---|---|---|
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Private Equity Investor | 31/07/2019 |
| ABLYNX | Directeur/Membre du Conseil | 07/11/2013 |
Akubio Ltd.
 Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Directeur/Membre du Conseil | 31/05/2010 |
| ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
| ░░░░░░░░░░ ░░░░░░░░░░░ ░░░ ░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Stephen William Bunting
| The University of Reading | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GALAPAGOS NV | Health Technology |
| Entreprise privées | 20 |
|---|---|
Aurora Biosciences Corp.
 Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Health Technology |
Cantab Pharmaceuticals Plc
 Cantab Pharmaceuticals Plc MiscellaneousMiscellaneous Cantab Pharmaceuticals plc, based in Cambridge, England, was established in 1989 to exploit advances in immunology. Since that time, Cantab has become a leader in the areas of immunotherapy and gene delivery and has developed a broad portfolio of novel products for the treatment and prevention of many chronic infectious diseases, cancer and substance addiction. | Miscellaneous |
Akubio Ltd.
Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Electronic Technology |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Finance |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Finance |
N.M. Rothschild & Sons Ltd.
 N.M. Rothschild & Sons Ltd. Major BanksFinance N.M. Rothschild & Sons Ltd. provides banking and financial services. It offers investment and commercial banking, treasury, merchant banking, fund management, private banking and trust management services to governments, corporations and individuals. The company has operations in USA, Zimbabwe, South Africa, Switzerland, United Arab Emirates, Sweden, Turkey, Singapore, Russia and Spain. N.M. Rothschild & Sons was founded in 1809 and is headquartered in London, the United Kingdom. | Finance |
Genetic Therapy, Inc.
 Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Commercial Services |
Hexagen Plc
 Hexagen Plc BiotechnologyHealth Technology Part of Incyte Corp., Hexagen Plc develops technology for the discovery of single nucleotide polymorphisms. The British company was founded by Andrew Peter Sandham, Stephen William Bunting. Hexagen was acquired by Incyte Corp. on September 22, 1998 for $25.99 million. | Health Technology |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Astex Therapeutics Ltd.
 Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Health Technology |
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
| Abingworth Bioventures V GP Ltd. | |
| Abingworth Bioventures IV GP Ltd. | |
Abingworth Bioventures IIA GP Ltd.
 Abingworth Bioventures IIA GP Ltd. Financial ConglomeratesFinance Abingworth Bioventures IIA GP Ltd. engages in the provision of financial and insurance services. The company was founded on June 20, 2002 and is headquartered in London, the United Kingdom. | Finance |
Prosensa Holding NV
 Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
| Abingworth Ventures (GP) Ltd. | |
| Abingworth Trustee Ltd. | |
| Elkinbrook Ltd. | |
Abingworth Management Holdings Ltd.
Abingworth Management Holdings Ltd. Investment ManagersFinance Part of Abingworth LLP, Abingworth Management Holdings Ltd. is a British company that engages in the management of investment funds. The company is based in London, UK. Founded in 1989. | Finance |
